+

WO1988002600A1 - Enzyme-containing bactericidal composition, and dental and wound treatment preparations comprising this composition - Google Patents

Enzyme-containing bactericidal composition, and dental and wound treatment preparations comprising this composition Download PDF

Info

Publication number
WO1988002600A1
WO1988002600A1 PCT/DK1987/000130 DK8700130W WO8802600A1 WO 1988002600 A1 WO1988002600 A1 WO 1988002600A1 DK 8700130 W DK8700130 W DK 8700130W WO 8802600 A1 WO8802600 A1 WO 8802600A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
enzyme
wound treatment
peroxidase
glucose
Prior art date
Application number
PCT/DK1987/000130
Other languages
French (fr)
Inventor
Otto Melchior Poulsen
Original Assignee
Otto Melchior Poulsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otto Melchior Poulsen filed Critical Otto Melchior Poulsen
Priority to FI882947A priority Critical patent/FI882947A0/en
Publication of WO1988002600A1 publication Critical patent/WO1988002600A1/en
Priority to NO882708A priority patent/NO882708L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • This invention relates to a bactericidal composition of the type containing at least one enzyme which in aqueous milieu and in the presence of oxygen and a substrate may form oxygen peroxide together with a peroxidase and a thiocyanate.
  • the bactericidal composition according to the invention is generally applicable, but as the composition is primarily developed and tested with respect to preparing a composition for the prevention and treatment of gingivitis and paradentosis, the invention will be more particularly explainde in the following with a view to obtaining a solution of this problem.
  • dental plaque depositing on the tooth surfaces as bacterial coatings which contain more or less protein and carbon hydrate substances, epithelial cells and food debris or stimulant debris are sharing the responsibility for caries, dental calculus, gingivitis and paradentosis.
  • Certain of the bacteria synthesize some strongly adhesive carbon hydrates (dextrans) from carbon hydrates of the intaken foodstuffs or stimulants and particularly sucrose constitutes the major basis of the formation of the dextrans.
  • the bacteria in plaques develop organic acids, in particular lactic acid and acetic acid due to the fermentative decomposition and reaction of the particularly decomposable mono- and disaccharides occurring in or developed from intaken foodstuffs and stimulants.
  • Dental calculus occurs as a cause of a minirali zation of dental plaque having a tendency to accumulate calcium and phosphate. If dental plaques are not regularly removed, e.g. by tooth brushing the accumulation of calcium and phosphates will reach a stage where a coherent and wear-resisting network of hydroxy apatite embedding the bacteria develops on the surfaces of the teeth.
  • the progressing dental calculus in which hydroxy apatite amounts to 80% of the total material of dental calculus has a tendency to grow, because the bacteria in dental calculus cannot be removed by ordinary tooth brushing.
  • dental calculus develops typically in areas of the teeth that are difficult to clean by tooth brushing. In this context the tooth surfaces facing the spaces between the teeth are particularly important. Dental calculus deposited between the tooth spaces will be spread therefrom and further on to the spaces between the teeth and gingivae, following which the dental calculus under gingivae will be spread from the tooth spaces to other areas of the teeth. In more advanced stages the dental calculus occurs on large areas between gingivae and the neck of the teeth and the organic acids generated by the acids will not only demineralize the teeth but also the bone structures located behind gingivae.
  • Said chemical compounds are said to derange, thereby confining the formation of dextran gels from sucrose caused by the bacteria.
  • the method does not have the intended effect on bacterial coatings in the teeth spaces where plaques are difficult to remove and where adhering food residues most frequently ensure that the bacteria have free access to low-molecular carbon hydrates.
  • the method does not have any effect on already developed dental calculus and, therefore, this method is held to be less suited with respect to the inhibition of gingivitis and paradentosis.
  • dextran gels generated in plaques are according to the accepted German patent application No. 1,955,956 proposed to be broken down by dextranases. According to AT patent No. 318,815 it has, however, been found that dextranase was merely capable of breaking down soluble dextran, while in plaques there is some of the insoluble dextran that cannot be broken down. According to US patent No. 4,154,815 dental plaque is confined by making use of zinc in connection with proteases, carbohydrases and/or Upases. Zinc has been found to be active by interference with the plaque structure and the mineralization of plaques, while the enzymes are entitled to decompose the plaques densifying high-polymeric compositions. A clinical experiment referred to in said patent demonstrates that zinc and protease were capable of reducing the amount of plaques on teeth surfaces, but the experimental report says nothing about the effect in the spaces between the teeth and on dental calculus.
  • DK patent application No. 5504/78 discloses a caries inhibiting dental hygiene agent in tablet form or powder form, said agent containing only lysozyme as an active component. This reference does not specify the type of lysozyme applied.
  • dental hygiene agents regularly used for long periods of time include antibiotics interfering in the intended microflora balance within the mouth, e.g. in connection with developing resistance.
  • German patent application No. 2,027,019 and the parallel US patent No. 4,150,113 deal with a dental hygiene agent containing an addition of oxidoreductase which by oxidative decomposition of a substrate causes hydrogen peroxide to be liberated. This is asserted to provide for obtaining a caries inhibiting effect.
  • the glucose acting as a substrate is said to be obtained from food debris in the mouth containing for example starcj or desaccharides, becouse the centifrice may as well contain carbohydrases generating glucose from the poly- or disaccharides concdrned.
  • EP patent application No. 133,736 relates to dentifrice compositions having an antibacterial activity and are based on the formation of hypothiocyanate (OSCN-) during utilization.
  • the agents concerned contain an oxidable substrate and an oxidoreductase system specific of said substrate and which in the presence of oxygen in aqueous milieu generates hydrogen peroxide which by reaction wit ⁇ the thiocyanate that is further contained in the agent generates hypothiocyanate under the influence of lactose peroxidase.
  • the agents contain for example glucose as an oxidable substrate, which is oxidized with glucose oxidase under the formation of hydrogen peroxide reacting with thiocyanate (SCN-) added for instance in the form of potassium thiocyanate, and with lactoperoxidase to produce the bacteriostatic hypothiocyanate (OSCN-).
  • SCN- thiocyanate
  • OSCN- lactoperoxidase
  • the agent is proposed to be used in inhibiting caries and for that purpose a bacteriostatic activity may per se provide for obtaining an advantageous effect.
  • a bactericidal activity is, however, not sufficient, since bacterial plaques in the spaces between the teeth and in gingival pockets will continue their growth upon decline of the inhibiting efficacy of the hypothiocyanate.
  • hypothiocyanate-forming system is therefore supposed to afford only a limited effect on the development of gingivitis and paradentosis and a proper inhibition can hardly be obtained thereby.
  • An effective inhibition and treatment of gingivitis and paradentosis can solely be obtained by extinguishing the bacteria localized between the teeth and in the gingival pockets. None of the above mentioned methods of inhibiting the formation of plaques either by preventing dextrans from forming or by attenuating or possibly extinguishing the bacteria involved proves any properly substantiated effect on plaques occurring between the teeth and in gingival pockets and the primary object of the inventions referred to actually also consists in the inhibition of caries.
  • composition according to the invention containing at least one enzyme which in aqueous milieu and in the presence of oxygen and a substrate for the enzyme is capable of generating hydrogen peroxide and a peroxidase and a thiocyanate, the composition according to the invention being characterized in that it further contains lysozyme.
  • the hydrogen peroxide forming enzyme When the bactericidal composition according to the invention, for example in prophylaxis or treatment of gingivitis or paradentosis, is applied in use between the tooth spaces and into the gingival pockets, the hydrogen peroxide forming enzyme will come into contact with food debris and stimulant debris containing substances acting as substrate for the enzyme. This entails oxidation of said substances under the liberation of hydrogen peroxide which by the influence of the peroxidase contained in the composition and naturally available peroxidase is reacted with thiocyanate, thereby generating hypothiocyanate (OSCN-).
  • OSCN- hypothiocyanate
  • composition according to the invention is characterized in that the hydrogen peroxide forming enzyme is glucose oxidase.
  • composition when the composition is to be used in connection with dental hygiene it may be appropriate that it further contains invertase or lactase or both, so that sucrose or lactose present in the oral cavity are decomposed under the formation of glucose serving as substrate for the glucose oxidase.
  • invertase or lactase or both sucrose or lactose present in the oral cavity are decomposed under the formation of glucose serving as substrate for the glucose oxidase.
  • the composition may in itself contain a substrate, also when used for dental hygiene, in which case the formation of hydrogen peroxide is not restricted by the amount of substances naturally present in the oral cavity and which act as substrate for the hydrogen peroxide forming enzyme.
  • a composition according to the invention which contains glucose oxidase is particularly intended to be used for wound treatment, it is expedient that it further includes glucose or glucose forming combinations of materials as substrate for the glucose oxidase and has a water content not exceeding the lowest value at which the glucose oxidase is active.
  • the reactions resulting in the generation of hypothiocyanate attenuating bacteria and causing them to be extinguished by the lysozyme occur only when the composition comes into contact with water, e.g. in the form of blood or lymph and, consequently, the composition is stable until use.
  • the composition may as well contain no glucose, but if so, it is used together with a glucose- containing or forming agent.
  • the alternatively hydrogen peroxide forming enzyme may be an amino acid oxidase, in which case the amino acida present in blood and lymph act as substrate.
  • the peroxidase constituting a component of the composition and ensuring the formation of hypothiocyanate from the thiocyanate and the hydrogen peroxide is lactoperoxidase, myeloperoxidase or horseradish peroxidase, all of which enzymes are classified E.C.1.17.1.7 (IUPAC).
  • the invention further relates to dental hygiene preparations that are particularly suitable to ensure a selectively high mortality of bacteria in tooth spaces and in the gingival pockets without affecting the microflora in the oral cavity.
  • a general affection on the total microflora in the oral cavity is incidentally undesired.
  • the dental hygiene agents according to the invention may be in the form of toothpicks, tooth thread of miniature brushes, in particular for the prevention and treatment of gingivitis and paradentosis and are characterized in that they are impregnated with the above mentioned composition according to the invention.
  • the impregnation of for example tooth picks may be effected by humidifying them with solutions of the hydrogen peroxide forming enzyme, peroxidase, thiocyanate and lysozyme and stabilizing agents known per se for enzymes followed by drying, for instance freeze drying, of the humidified tooth picks.
  • the dentifrice may be in the form of a solution or suspension adapted to be introduced into the spaces between the teeth and gingival pockets by means of a brush, tooth thread, toothpicks or the like, said solution containing the hydrogen peroxide generating enzyme, peroxidase, thiocyanate and lysozyme, preferably together with ordinary stabilizing and preservating agents.
  • the bactericidal effect of the composition according to the invention is so high that the comparatively small amount of the components of the composition that may be added by means of impregnated toothpicks will be sufficient to thereby obtain a markable bactericidal effect.
  • the composition by treatment or prophylaxis of gingivitis and paradentosis for example by means of toothpicks is applied locally into gingival pockets and the spaces between the teeth, this composition may advantageously also be used in other dental hygiene agents, such as toothpaste the use of which only affords an inferior localized supply.
  • the composition according to the invention will obvious also be applicable in combination with other agents for enhancing the intended effect.
  • the EDTA will be capable of enhancing the effect of the composition on bacteria having a content of calcium conpounds in the cell walls.
  • the bactericidal composition is to be used for wound treatment a dressing material may be impregnated with it, ot the composition may constitute a component of a vulneary powder.
  • the composition is principally generally applicable else- where, it an effective bactericidal activity is desired which is gentle to the host organism and has a limited duration and which does not involve the same risk of forming resistant strains of micro organisms as when using antibiotics.
  • the composition according to the invention may be prepared by use of such enzymes, all of which are approved for use in foodstuffs.
  • the quantitaive ratios between the components of the bactericidal composition concerned may vary within a wide range.
  • Lactase ⁇ -galactosidase (E.C. 3.2.1.23) is given in the unit L.U. (Lactase unit) defined as the amount of enzyme producing in one minute 1 mg glucose from 6 ml of 5.0% lactose at 20°C and pH 6.5.
  • Invertase ⁇ -fructofuranosidase (E.C. 3.2.1.26) is given in S.U. (Sumner Unit) defined as the amount of enzyme generating in five minutes 1 mg invert sugar from 6 ml of 5 .4% sucrose at 20°C and pH 4.7.
  • Glucose oxidase is classified E.C. 1.1.3.4.
  • Lactoperoxidase is classified E.C. 1.17.1.7. and has the function in the composition concerned to catalyze the reaction H 2 O 2 + SCN ⁇ H 2 O
  • Lysozyme also designated muramidase, is N-acetylmura- mylhydrolase (E.C. 3.2.1.17). This enzyme decomposes N-acethylglucosamine and N-acetylmuramic acid from the cell walls.
  • the activity of lysozyme is measured by lysing of Micrococcus lysodieticus. As a well defined standard of the activity is difficult to determine, the amount of the lysozyme applied is, however, given in absolute values in the following examples.
  • the material as used had a purity of 99% and was extracted from egg white.
  • the bacterial cultures were subsequently incubated for three days at temperatures of 25, 37, 40 or 45°C, during which intervals the cultures were daily inspected. It turned out that in every case the baterial growth ceased even with an addition of only 50 ⁇ l of the solution per 10 ml growth culture.
  • the toothpicks were subsequently freeze-dried. With a view to testing the bactericidal effect of the toothpicks thus impregnated, 10 5 bacteria of different strains of the genera Streptococcus and Lactobacillus were incubated on agar plates.
  • the tooth picks that were impegnated with the composition according to the invention were pressed down into the sucrose- containing agar plates which were then incubated for six days, and the growth was daily observed. Tests were carried out by incubation at 25°C as well as at 40°C, and in particular at 37°C. A clear zone had formed around the toothpicks, completely free of bacterial growth in an area varying between 5 and 15 mm reckoned from the toothpick.
  • toothpicks were impregnated with an aqueous buffer solution of lysozyme and EDTA in the above quoted amounts but without enzymes and NaSCN. Said latter toothpicks could not prove any significant bactericidal actvity by the test carried out.
  • Distilled water ad 100 ml It can be calculated that in use such a solution will be diluted about three times by saliva available in gingival pockets and on the surfaces of the tooth necks. The resulting concentration of the components contained in the composition to about one fourth of the above specified values will be completely sufficient to obtain the desired bacteriostatic activity.
  • Example 5 An aqueous solution as in Example 5 was prepared but without invertase and colour and flavourings. Gauze wads were drenched with the solution and subsequently dried in vacuum. The resulting wound dressing material was suitable to be used in connection with a vulnerable powder containing besides the components ordinary of such a powder, about 2% by weight of glucose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A bactericidal composition containing a hydrogen peroxide forming enzyme, particularly glucose oxidase and peroxidase, especially lactoperoxidase, a thiocyanate and lysozyme. During use hydrogen peroxide is generated which under the influence of the peroxidase converts the thiocyanate into hypothiocyanate (OSCN-) attenuating bacteria in such a manner that they are lysed by the lysozyme. The composition is particularly appropriate in prophylaxis and treatment of gingivitis and paradentosis, in which cases it is used locally, e.g. applied as impregnating agent on tooth picks.

Description

Enzyme-Containing Bactericidal Composition, and Dental and Wound Treatment Preparations Comprising this Composition.
This invention relates to a bactericidal composition of the type containing at least one enzyme which in aqueous milieu and in the presence of oxygen and a substrate may form oxygen peroxide together with a peroxidase and a thiocyanate.
The bactericidal composition according to the invention is generally applicable, but as the composition is primarily developed and tested with respect to preparing a composition for the prevention and treatment of gingivitis and paradentosis, the invention will be more particularly explainde in the following with a view to obtaining a solution of this problem.
It is generally accepted that dental plaque depositing on the tooth surfaces as bacterial coatings which contain more or less protein and carbon hydrate substances, epithelial cells and food debris or stimulant debris are sharing the responsibility for caries, dental calculus, gingivitis and paradentosis. Certain of the bacteria synthesize some strongly adhesive carbon hydrates (dextrans) from carbon hydrates of the intaken foodstuffs or stimulants and particularly sucrose constitutes the major basis of the formation of the dextrans. The bacteria in plaques develop organic acids, in particular lactic acid and acetic acid due to the fermentative decomposition and reaction of the particularly decomposable mono- and disaccharides occurring in or developed from intaken foodstuffs and stimulants. The resulting organic acids attack and demineralize the enamel and subsequently the tooth pulp by extracting calcium and phosphate, meaning the outbreak and development of caries. Dental calculus occurs as a cause of a minirali zation of dental plaque having a tendency to accumulate calcium and phosphate. If dental plaques are not regularly removed, e.g. by tooth brushing the accumulation of calcium and phosphates will reach a stage where a coherent and wear-resisting network of hydroxy apatite embedding the bacteria develops on the surfaces of the teeth. The progressing dental calculus in which hydroxy apatite amounts to 80% of the total material of dental calculus has a tendency to grow, because the bacteria in dental calculus cannot be removed by ordinary tooth brushing. The clinical correlation between dental calculus and gingivitis has long been known and this correlation has been demonstrated several times. It is likewise known that non-treated gingivitis progresses into paradentosis as time goes by. Dental calculus develops typically in areas of the teeth that are difficult to clean by tooth brushing. In this context the tooth surfaces facing the spaces between the teeth are particularly important. Dental calculus deposited between the tooth spaces will be spread therefrom and further on to the spaces between the teeth and gingivae, following which the dental calculus under gingivae will be spread from the tooth spaces to other areas of the teeth. In more advanced stages the dental calculus occurs on large areas between gingivae and the neck of the teeth and the organic acids generated by the acids will not only demineralize the teeth but also the bone structures located behind gingivae.
Various ways have been followed in the attempts made so far with a view to confine and inhibit the formation of plaques. These consist principally in either preventing the formation of the dextran gels causing the plaques to attach to the tooth surfaces or in impeding the growth of bacteria by making use of chemical compounds acting growth-inhibiting or bactericidally and which in certain cases are produced in situ. Several mathods of preventing the formation of dextran have been suggested . According to the accapted German specification No. 1,467,809 salts of calcium, sodium or magnesium salts of esters of phosphoric acids with sucrose, glucose or lactose can work as sarlostatic dental hygiene agents. Said chemical compounds are said to derange, thereby confining the formation of dextran gels from sucrose caused by the bacteria. However, the method does not have the intended effect on bacterial coatings in the teeth spaces where plaques are difficult to remove and where adhering food residues most frequently ensure that the bacteria have free access to low-molecular carbon hydrates. Moreover, the method does not have any effect on already developed dental calculus and, therefore, this method is held to be less suited with respect to the inhibition of gingivitis and paradentosis.
According to US patent No. 3,733,399 the formation of dental plaques as a precursor to caries is claimed to be confined by invertase that breaks down the disaccharide sucrose into two monomers: anhydroglucose and fructose. The dextran gels formed in plaques are sain only to be synthesized by the bacteria from sucrose and the effect of invertase should apparently be to reduce the amount of sucrose accessible for the becteria. The use of invertase together with lactate dehydrogenase is according to US patent No..4, 255 ,414 likewise claimed to possess an anticaries effect. It is, however, known that cariogenic bacteria, for instance Streptococcus mutans, on their own form invertaseous enzymes breaking down sucrose into anhydroglucose and fructose, said bacteria being likely to form dextran gels from anhydroglucose obtained from their own enzymes as well as from invertase applied with a dental hygiene agent. It is further known that dental plaques are also formed if the intaken foodstuffs contain carbon hydrates, such as starch or lactose, instead of sucrose, and invertase contained in dental hygiene agents cannot be expected to have any action on the plaques formation in those cases. Eventually, invertase does not have any action on already formed plaques and dental calculus and invertase is thus only of minor importance with respect to inhibition and is of no importance in relation to the treatment of gingivitis and paradentosis.
The dextran gels generated in plaques are according to the accepted German patent application No. 1,955,956 proposed to be broken down by dextranases. According to AT patent No. 318,815 it has, however, been found that dextranase was merely capable of breaking down soluble dextran, while in plaques there is some of the insoluble dextran that cannot be broken down. According to US patent No. 4,154,815 dental plaque is confined by making use of zinc in connection with proteases, carbohydrases and/or Upases. Zinc has been found to be active by interference with the plaque structure and the mineralization of plaques, while the enzymes are entitled to decompose the plaques densifying high-polymeric compositions. A clinical experiment referred to in said patent demonstrates that zinc and protease were capable of reducing the amount of plaques on teeth surfaces, but the experimental report says nothing about the effect in the spaces between the teeth and on dental calculus.
DK patent application No. 5504/78 discloses a caries inhibiting dental hygiene agent in tablet form or powder form, said agent containing only lysozyme as an active component. This reference does not specify the type of lysozyme applied.
According to US patent No. 3,985,869 neither egg white lysozyme nor enzymes obtained by Streptomyces albus or Streptomyces griseus or a strain belonging to the genus Flavobacterium are capable of lysing carioge nic bacteria belonging to the genera Streptococcus and Lactobacillus. According to said reference it is, however, possible by means of four different strains of Streptomyces to produce cell lysing enzymes capable of attacking cariogenic streptococci and lactobaclllius. As known, there exists, however, a somewhat cautious attitude with respect to applying enzymes produced from Streptomyces to agents intended for use e.g. in the oral cavity or for wound treatment, because various strains of Streptomyces develop substances, the presence of which is not desired in such agents and which might be difficult to remove from the desired enzymes obtainable from the strains of Stretomyces. Thus, it is generally not desired that for example dental hygiene agents regularly used for long periods of time include antibiotics interfering in the intended microflora balance within the mouth, e.g. in connection with developing resistance.
The accepted German patent application No. 2,027,019 and the parallel US patent No. 4,150,113 deal with a dental hygiene agent containing an addition of oxidoreductase which by oxidative decomposition of a substrate causes hydrogen peroxide to be liberated. This is asserted to provide for obtaining a caries inhibiting effect. The glucose acting as a substrate is said to be obtained from food debris in the mouth containing for example starcj or desaccharides, becouse the centifrice may as well contain carbohydrases generating glucose from the poly- or disaccharides concdrned. According to experiments by which the obtainable effect is randered probable in said references unphysiologically high concentrations of sucrose were, however, added immediately before the addition of the enzymes and it must be considered improbable that concertrations of hydrogen peroxide sufficient to inhibit or impede the growth ofbacteria to a desired degree will be obtained by using the agent in practice in connection with the intake of foodstuffs more ordinarily made up.
The specification of US patent No. 4,476,108 states that the bactericidal efficacy of hydrogen peroxide intensifies by the addition of peroxidase and electron-donor molecules which by reaction generate free radicals having a high bactericidal activity. Horseradish peroxidase is the preferred peroxidase, while the electron donors are organic molecules among which the following are recited; phenylethylamine, tyrosine, tryptophan, benzoic acid, salicylic acid, hydroquinone, dehydrophenylalanine, vanillan and para-aminobenzoic acid. The presence of hydrogen peroxide is obtained in that the bactericidal agent concerned has a content of hydrogen peroxide, sodium peroxide, methyl peroxide or ethyl peroxide.
EP patent application No. 133,736 relates to dentifrice compositions having an antibacterial activity and are based on the formation of hypothiocyanate (OSCN-) during utilization. The agents concerned contain an oxidable substrate and an oxidoreductase system specific of said substrate and which in the presence of oxygen in aqueous milieu generates hydrogen peroxide which by reaction witϊϊ the thiocyanate that is further contained in the agent generates hypothiocyanate under the influence of lactose peroxidase. In a typical embodiment the agents contain for example glucose as an oxidable substrate, which is oxidized with glucose oxidase under the formation of hydrogen peroxide reacting with thiocyanate (SCN-) added for instance in the form of potassium thiocyanate, and with lactoperoxidase to produce the bacteriostatic hypothiocyanate (OSCN-).
The agent is proposed to be used in inhibiting caries and for that purpose a bacteriostatic activity may per se provide for obtaining an advantageous effect. For the prevention and treatment of gingivitis and para dentosis a bactericidal activity is, however, not sufficient, since bacterial plaques in the spaces between the teeth and in gingival pockets will continue their growth upon decline of the inhibiting efficacy of the hypothiocyanate.
The use of the hypothiocyanate-forming system is therefore supposed to afford only a limited effect on the development of gingivitis and paradentosis and a proper inhibition can hardly be obtained thereby. An effective inhibition and treatment of gingivitis and paradentosis can solely be obtained by extinguishing the bacteria localized between the teeth and in the gingival pockets. None of the above mentioned methods of inhibiting the formation of plaques either by preventing dextrans from forming or by attenuating or possibly extinguishing the bacteria involved proves any properly substantiated effect on plaques occurring between the teeth and in gingival pockets and the primary object of the inventions referred to actually also consists in the inhibition of caries.
There is therefore a need for a bactericidal composition capable of ensuring a high mortality of bacteria, particularly in the areas of the oral cavity where the bacteria give rise to gingitivis or paradentosis.
It has now surprisingly been found that bacteria of the types that are considered to be responsible for the occurrence and progressing of gingivitis and paradentosis, which bacteria as stated above cannot be di- rectly lysed and extinguished by the cell wall decomposing enzyme lysozyme, after having been attenuated with hypothiocyanate (OSCN-) to a much higher degree are broken down and extinguished by said enzyme.
Use is made of this recognition with respect to the bactericidal composition according to the invention containing at least one enzyme which in aqueous milieu and in the presence of oxygen and a substrate for the enzyme is capable of generating hydrogen peroxide and a peroxidase and a thiocyanate, the composition according to the invention being characterized in that it further contains lysozyme.
When the bactericidal composition according to the invention, for example in prophylaxis or treatment of gingivitis or paradentosis, is applied in use between the tooth spaces and into the gingival pockets, the hydrogen peroxide forming enzyme will come into contact with food debris and stimulant debris containing substances acting as substrate for the enzyme. This entails oxidation of said substances under the liberation of hydrogen peroxide which by the influence of the peroxidase contained in the composition and naturally available peroxidase is reacted with thiocyanate, thereby generating hypothiocyanate (OSCN-). This affects the available, undesired bacteria in such a manner that they become sensitive to and killed by the lysozyme contained in the composition and which would not have been able to break down the bacteria, if they had not been attenuated by the hypothiocyanate.
A preferred embodiment of the composition according to the invention is characterized in that the hydrogen peroxide forming enzyme is glucose oxidase.
In particular when the composition is to be used in connection with dental hygiene it may be appropriate that it further contains invertase or lactase or both, so that sucrose or lactose present in the oral cavity are decomposed under the formation of glucose serving as substrate for the glucose oxidase. This provides for obtaining not only an appropriate formation of hydrogen peroxide which further results in a formation of hypothiocyanate but also a removal of said undesired disaccharides.
However, the composition may in itself contain a substrate, also when used for dental hygiene, in which case the formation of hydrogen peroxide is not restricted by the amount of substances naturally present in the oral cavity and which act as substrate for the hydrogen peroxide forming enzyme. If a composition according to the invention which contains glucose oxidase, is particularly intended to be used for wound treatment, it is expedient that it further includes glucose or glucose forming combinations of materials as substrate for the glucose oxidase and has a water content not exceeding the lowest value at which the glucose oxidase is active.
The reactions resulting in the generation of hypothiocyanate attenuating bacteria and causing them to be extinguished by the lysozyme occur only when the composition comes into contact with water, e.g. in the form of blood or lymph and, consequently, the composition is stable until use. The composition may as well contain no glucose, but if so, it is used together with a glucose- containing or forming agent. When the composition according to the invention is intended to be used for wound treatment, the alternatively hydrogen peroxide forming enzyme may be an amino acid oxidase, in which case the amino acida present in blood and lymph act as substrate. In preferred embodiments of the composition the peroxidase constituting a component of the composition and ensuring the formation of hypothiocyanate from the thiocyanate and the hydrogen peroxide is lactoperoxidase, myeloperoxidase or horseradish peroxidase, all of which enzymes are classified E.C.1.17.1.7 (IUPAC).
As mentioned, a particular interest is attached to the application of the composition in dental hygiene agents and the invention further relates to dental hygiene preparations that are particularly suitable to ensure a selectively high mortality of bacteria in tooth spaces and in the gingival pockets without affecting the microflora in the oral cavity. A general affection on the total microflora in the oral cavity is incidentally undesired.
The dental hygiene agents according to the invention may be in the form of toothpicks, tooth thread of miniature brushes, in particular for the prevention and treatment of gingivitis and paradentosis and are characterized in that they are impregnated with the above mentioned composition according to the invention. The impregnation of for example tooth picks may be effected by humidifying them with solutions of the hydrogen peroxide forming enzyme, peroxidase, thiocyanate and lysozyme and stabilizing agents known per se for enzymes followed by drying, for instance freeze drying, of the humidified tooth picks.
Alternatively, the dentifrice may be in the form of a solution or suspension adapted to be introduced into the spaces between the teeth and gingival pockets by means of a brush, tooth thread, toothpicks or the like, said solution containing the hydrogen peroxide generating enzyme, peroxidase, thiocyanate and lysozyme, preferably together with ordinary stabilizing and preservating agents.
Experiments have proven that the bactericidal effect of the composition according to the invention is so high that the comparatively small amount of the components of the composition that may be added by means of impregnated toothpicks will be sufficient to thereby obtain a markable bactericidal effect. Even though it is a particular feature of the invention that the composition by treatment or prophylaxis of gingivitis and paradentosis for example by means of toothpicks is applied locally into gingival pockets and the spaces between the teeth, this composition may advantageously also be used in other dental hygiene agents, such as toothpaste the use of which only affords an inferior localized supply. incidentally, the composition according to the invention will obvious also be applicable in combination with other agents for enhancing the intended effect. Thus, the EDTA will be capable of enhancing the effect of the composition on bacteria having a content of calcium conpounds in the cell walls.
In case the bactericidal composition is to be used for wound treatment a dressing material may be impregnated with it, ot the composition may constitute a component of a vulneary powder.
Even though the bactericidal composition has mainly been described in the preceding in connection with its use for dental care or wound treatment, the composition is principally generally applicable else- where, it an effective bactericidal activity is desired which is gentle to the host organism and has a limited duration and which does not involve the same risk of forming resistant strains of micro organisms as when using antibiotics. In this respect it is emphasized that the composition according to the invention may be prepared by use of such enzymes, all of which are approved for use in foodstuffs.
The quantitaive ratios between the components of the bactericidal composition concerned may vary within a wide range. In view of the fact that the components individually must be considered to be non-toxic there is no risk that an overdose will cause disadvantageous side effect, this particularly applies to dental hygiene agents which in themselves do not contain a substrate for the hydrogen peroxide generating enzyme so that the maximum amount of generated hypothiocyanate is determined by the amount of foodstuff and stimulant residues remaining on the localities concerned in the mouth.
The quantitative composition of various preparations according to the invention that have proven effective will appear from the following examples. With a view to further characterizing the enzymes used in the examples and the units of quantities therefor, the following is to be noticed.
Lactase: β-galactosidase (E.C. 3.2.1.23) is given in the unit L.U. (Lactase unit) defined as the amount of enzyme producing in one minute 1 mg glucose from 6 ml of 5.0% lactose at 20°C and pH 6.5. Invertase: β-fructofuranosidase (E.C. 3.2.1.26) is given in S.U. (Sumner Unit) defined as the amount of enzyme generating in five minutes 1 mg invert sugar from 6 ml of 5 .4% sucrose at 20°C and pH 4.7. Glucose oxidase is classified E.C. 1.1.3.4. and is given in the unit GOU (glucose oxidase unit) defined by D. Scott in J.Agri. Food Chem. 153 (1): 727 (1953). Lactoperoxidase is classified E.C. 1.17.1.7. and has the function in the composition concerned to catalyze the reaction H2O2 + SCN→ H2O
+ OSCN-. This enzyme is given in ABTS units as defined by J.S. Shindler and W.G. Bardsley: (Biochem. Biophys. Res. Commun. 67: 1307 (1975)).
Lysozyme, also designated muramidase, is N-acetylmura- mylhydrolase (E.C. 3.2.1.17). This enzyme decomposes N-acethylglucosamine and N-acetylmuramic acid from the cell walls. The activity of lysozyme is measured by lysing of Micrococcus lysodieticus. As a well defined standard of the activity is difficult to determine, the amount of the lysozyme applied is, however, given in absolute values in the following examples. The material as used had a purity of 99% and was extracted from egg white.
EXAMPLE 1
A solution containing the following ingredients per ml was prepared:
Invertase 900 S U
Glucose oxidase 45 GOU NaSCN 0.05
Lacto peroxidase 28 ABTS-units
Lysozyme 0.03 g
Sodium EDTA 0.05 mmol in an aqueous buffer containing 10 to 200 mM Na2HPO4/NaH2PO4 at pH 6.0.
With a view to testing the bactericidal effect of the composition thus obtained in the presence of a substrate various organisms belonging to the genera streptococcus, Lactobacillus, Bacteroides, Flovobacterium and Fusobacterlum were individually cultured in a favourable growth medium. When the organisms had obtained balanced growth with a cellular density of 105 to 107 cells/ml the above solution was added to the cultures in an amount ranging between 50 to 200 μl/10 ml culture. At the same time sucrose was added in an amount ranging between 0.1 and 1% in order to start the reaction eventually resulting in the OSCN-. The bacterial cultures were subsequently incubated for three days at temperatures of 25, 37, 40 or 45°C, during which intervals the cultures were daily inspected. It turned out that in every case the baterial growth ceased even with an addition of only 50 μl of the solution per 10 ml growth culture.
EXAMPLE 2 A solution was prepared containing the following ingredients per ml:
Invertase 900 S U
Glucose oxidase 45 GOU
NaSCN 0.05 mmol Lactoperoxidase 28 ABTS-units
Lysozyme 0.03 g
Mannitol 0.02 g
Sodium EDTA 0.05 mmol in a phosphate buffer at PH 6.0. The pique end of toothpicks was immersed into this solution causing that 5 to 7 μl of the solution adhered to each toothpick.
The toothpicks were subsequently freeze-dried. With a view to testing the bactericidal effect of the toothpicks thus impregnated, 105 bacteria of different strains of the genera Streptococcus and Lactobacillus were incubated on agar plates. The tooth picks that were impegnated with the composition according to the invention were pressed down into the sucrose- containing agar plates which were then incubated for six days, and the growth was daily observed. Tests were carried out by incubation at 25°C as well as at 40°C, and in particular at 37°C. A clear zone had formed around the toothpicks, completely free of bacterial growth in an area varying between 5 and 15 mm reckoned from the toothpick. The size of said clear zone was de pendent on the genus of bacteria used. In any case no bacteria colony was observed within the clear zone, even after a six-day growth, meaning that the bacteria in this zone had been extinguished and not only physiologically weakened.
A test was also carried out on the bactericidal effect of the impregnated toothpicks after the toothpicks had been stored in airtight packages at 20°C for three months. The bactericidal effect of said tooth- picks appeared to have been preserved completely unabated, thereby drawing the conclusion that the bactericidal composition according to the invention includes a storing stability sufficient for practical use. For the purpose of comparison toothpicks were impregnated in a similar manner with a solution as that outlined above but with no content of lysozyme. On testing the bactericidal effect of said toothpicks on agar plates results were obtained showing a considerably lower bactericidal effect compared to the effect obtained when lysozyme is also present.
For the purpose of drawing an additional comparison toothpicks were impregnated with an aqueous buffer solution of lysozyme and EDTA in the above quoted amounts but without enzymes and NaSCN. Said latter toothpicks could not prove any significant bactericidal actvity by the test carried out.
EXAMPLE 3 Preparation of a solution for impregnating tooththread containing the following ingredients:
Invertase 30000 S U Lactase 23000 L U
Glucose oxidase 1000 GOU
NaSCN 5 mmol
Lactoperoxidase 940 ABTS-units
Lysozyme 1.5 g Carboxymethylcellulose 0.5 g
Inositol 1.75 g
Sodium EDTA 5 mmol
Na2HPO4 to pH 6.5
Distilled water ad 100 ml
EXAMPLE 4
Preparation of a solution for impregnating tooth thread containing the following ingredients:
Invertase 90000 S U Lactase 70000 L U
Glucose oxidase 4500 GOU
NaSCN 5 mmol
Lactoperoxidase 940 ABTS- -units
Lysozyme 3 g Mannitol 1 g
Sorbitol 2 g
Sodium EDTA 5 mmol
Na2HPO4 to pH 6 .0
Colour and flavourings Distilled water ad 100 ml EXAMPLE 5 An aqueous solution into which toothpicks, tooththread or miniature brushes shall be immersed immediately before use was prepared from the folowing ingredients:
Invertase 1800 S U
Lactase 1400 L U
Glucose oxidase 80 GOU
NaSCN 0.1 mmol Lactoperoxidase 56 ABTS-units
Lysozyme 60 mg
Glycerol 20 g
EDTA 0.1 mmol
Na2HPO4 to pH 6.0 Colour and flavourings
Distilled water ad 100 ml It can be calculated that in use such a solution will be diluted about three times by saliva available in gingival pockets and on the surfaces of the tooth necks. The resulting concentration of the components contained in the composition to about one fourth of the above specified values will be completely sufficient to obtain the desired bacteriostatic activity.
EXAMPLE 6
An aqueous solution as in Example 5 was prepared but without invertase and colour and flavourings. Gauze wads were drenched with the solution and subsequently dried in vacuum. The resulting wound dressing material was suitable to be used in connection with a vulnerable powder containing besides the components ordinary of such a powder, about 2% by weight of glucose.

Claims

P A T E N T C L A I M S
1. A bactericidal cpmposition containing at least one enzyme which in aqueous milieu and in the presence of oxygen and a substrate for the enzyme may form oxygen peroxide together with a peroxidase adn a thiocyanate, characterized in that it further contains lysozyme.
2. A composition as claimed in claim 1, characterized in that the hycrogen peroxide forming enzyme is glucose oxidase.
3. A composition as claimed in claim 2, in particular for use in dental care, characterized in that ut further contains invertase or lactase or both.
4. A composition as claimed in claim 2, particularly for use in wound treatment, characterized in that it further contains glucose or glucose forming combinations of materials as a substrate for the glucose oxidase and has a water content below the smallest value at which the glucose oxidase is active.
5. A composition as claimed in claim 1, in particular for use in wound treatment, characterized in that the hydrogen peroxide generating enzyme is an amino acid oxidase.
6. A composition as claimed in any of the preceding claims, characterized in that the peroxidase is selected among the lactoperoxidase, myeloperoxidase and horseradish peroxidase classified in E.C. 1.17.1.7.
7. A dentifrice in the form of toothpicks, tooth thread or miniature brushes, in particular for the inhibition and treatment of gingivitis and paradentosis, characterized in that they are impregnated with a composition according to any of claims 1 to 3.
8. A dentifrice in the form of a solution or suspendion, in particular for the inhibition and treatment of gingivitis and paradentosis and adapted to be applied into the spaces between the teeth and gingival pockets, characterized in that it is an aqueous solution of a composition according to any of claims 1 to 3.
9. A wound treatment preparation, characterized in that it is a dressing material impregnated with a composition according to claims 4 or 5.
10. A wound treatment preparation, characterized in that it is a vulnerable powder containing a composition according to claims 4 ot 5.
PCT/DK1987/000130 1986-10-20 1987-10-19 Enzyme-containing bactericidal composition, and dental and wound treatment preparations comprising this composition WO1988002600A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI882947A FI882947A0 (en) 1986-10-20 1987-10-19 ENZYMINNEHAOLLANDE BAKTERIEDOEDANDE KOMPOSITION OCH VAORDPREPARAT FOER TAENDER OCH SAOR INNEHAOLLANDE DENNA KOMPOSITION.
NO882708A NO882708L (en) 1986-10-20 1988-06-17 ENZYMOUS BACTERICIDE MIXTURE AND DENTAL AND SPARE TREATMENTS CONTAINING THE MIXTURE.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK501686A DK501686A (en) 1986-10-20 1986-10-20 ENZYME CONTAINING BACTERICIDIC AGENTS AND DENTALS AND SPECIAL TREATMENTS CONTAINING IT
DK5016/86 1986-10-20

Publications (1)

Publication Number Publication Date
WO1988002600A1 true WO1988002600A1 (en) 1988-04-21

Family

ID=8138685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1987/000130 WO1988002600A1 (en) 1986-10-20 1987-10-19 Enzyme-containing bactericidal composition, and dental and wound treatment preparations comprising this composition

Country Status (6)

Country Link
EP (1) EP0293407A1 (en)
JP (1) JPH01501000A (en)
AU (1) AU8175087A (en)
DK (1) DK501686A (en)
FI (1) FI882947A0 (en)
WO (1) WO1988002600A1 (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651433A1 (en) * 1989-09-07 1991-03-08 Dana Dominique Enzyme complex having activity with respect to tartar and dental caries
WO1991006217A1 (en) * 1989-10-27 1991-05-16 Genencor International Europe Oy A process of combatting microorganisms
EP0461530A3 (en) * 1990-06-13 1992-06-03 Haarmann & Reimer Corp. Synergistic antimicrobial compositions
WO1992010165A1 (en) * 1990-12-05 1992-06-25 Warner-Lambert Company Enzyme containing denture cleanser
EP0500387A3 (en) * 1991-02-21 1992-10-28 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora using haloperoxidase
FR2685202A1 (en) * 1991-12-24 1993-06-25 Sederma Sa Novel method of pharmaceutical and cosmetic treatment for the regulation of seborrhoea, acne and the cutaneous flora
US5250299A (en) * 1991-09-23 1993-10-05 Haarmann & Reimer Corp. Synergistic antimicrobial compositions
FR2695034A1 (en) * 1992-09-01 1994-03-04 Oreal Cosmetic or pharmaceutical composition comprising in combination a peroxidase and a singlet anti-oxygen agent.
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
WO1995014784A1 (en) * 1993-11-24 1995-06-01 Monsanto Company Method of controlling plant pathogens
WO1996015682A1 (en) * 1994-11-22 1996-05-30 Ing. Erich Erber Kommanditgesellschaft Fodder and drinking water additive for improving the resistance to stress and immunity of useful animals
US5565197A (en) * 1991-02-21 1996-10-15 Exoxemis, Inc. Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases
US5607681A (en) * 1990-02-03 1997-03-04 The Boots Company Plc Anti-microbial compositions
WO1997026908A1 (en) * 1996-01-23 1997-07-31 Semper Aktiebolag Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
US5756090A (en) * 1991-02-21 1998-05-26 Eoe, Inc. Oxygen activatable formulations for disinfection or sterilization
WO1998049272A3 (en) * 1997-04-29 1999-02-04 Knoll Ag Enzyme concentrate
US5888505A (en) * 1991-02-21 1999-03-30 Eoe, Inc. Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system
FR2777785A1 (en) * 1998-04-27 1999-10-29 Sederma Sa Cosmetic and dermopharmaceutical compositions containing horseradish peroxidase and caffeic acid
FR2803199A1 (en) * 1999-12-29 2001-07-06 Jean Dominique Dana PROCESS FOR TRANSFORMATION OF CARIOGENOUS FOOD SUGARS INTO NEUTRAL ACARIOGENOUS OR CARIOSTATIC PRODUCTS AND COMPOSITION FOR IMPLEMENTATION
EP1010430A4 (en) * 1998-04-30 2004-03-31 Snow Brand Milk Products Co Ltd Preventives and ameliorating agents for periodontosis
EP0994716B2 (en) † 1997-07-25 2007-07-04 Westgate Biological Limited Maternal immune secretions and their use in the treatment and/or prophylaxis of conditions of the human body
WO2008041218A1 (en) * 2006-10-06 2008-04-10 Institute Of Technology Sligo Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme
EP2073836A4 (en) * 2006-10-10 2010-04-07 Laclede Inc Methods and compositions for the treatment of vaginal diseases employing peroxide-producing enzymes and peroxidases
WO2014191995A2 (en) 2013-05-27 2014-12-04 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
US8933147B2 (en) 2005-11-17 2015-01-13 3M Innovative Properties Company Anti-microbial dental impression material
US8945540B2 (en) 2008-05-09 2015-02-03 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
KR101498510B1 (en) * 2012-06-26 2015-03-04 서울대학교산학협력단 Artificial salivary composition comprising hyalulonic acid
FR3020758A1 (en) * 2014-05-12 2015-11-13 Jean-Dominique Dana COMPOSITION FOR IMPROVING BUCO-DENTAL HYGIENE
US9393249B2 (en) 2008-03-26 2016-07-19 Institute Of Technology Sligo Antimicrobial composition
US9522165B2 (en) 2006-10-06 2016-12-20 Institute Of Technology Sligo Formulation and method for the treatment of fungal nail infections
EP3192494A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192498A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192495A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
US9782459B2 (en) 2011-07-11 2017-10-10 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
EP3297442A4 (en) * 2015-05-18 2018-11-07 Zymtronix, LLC Magnetically immobilized microbiocidal enzymes
US10260061B2 (en) 2011-03-10 2019-04-16 Cornell University Mesoporous catalysts of magnetic nanoparticles and free-radical-producing enzymes, and methods of use
US10351841B2 (en) 2012-10-05 2019-07-16 Cornell University Method for inhibiting growth of microorganisms with macroporous scaffolds
EP3603654A1 (en) * 2014-11-24 2020-02-05 Matoke Holdings Limited Prevention and treatment of microbial infections
US10792649B2 (en) 2015-07-15 2020-10-06 Zymtronix, Llc Automated bionanocatalyst production
US10993436B2 (en) 2016-08-13 2021-05-04 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals
CN113317327A (en) * 2020-02-28 2021-08-31 中粮营养健康研究院有限公司 Bactericidal virucidal enzyme preparation composition and application thereof
US11185080B2 (en) 2014-04-30 2021-11-30 Matoke Holdings Limited Antimicrobial compositions
CN115633706A (en) * 2022-09-27 2023-01-24 深圳市减化生物科技有限公司 Biological sterilization mildew removing agent, preparation method thereof and cleaning product
US11730168B2 (en) 2017-10-16 2023-08-22 Matoke Holdings Limited Antimicrobial superabsorbent compositions
EP3192564B1 (en) * 2016-01-12 2024-07-10 Unilever IP Holdings B.V. Oral care composition comprising a protein for balancing the bacterial flora of the mouth

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2860154B1 (en) * 2003-09-29 2006-02-03 Chris Cardon COMPOSITION FOR THE TREATMENT OF MALE BREATH

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2852792A1 (en) * 1977-12-06 1979-06-07 Anic Spa CARIES PREVENTIVE DENTALCLEANING COMPOSITION
DE2937964A1 (en) * 1979-09-20 1981-03-26 Peter 3400 Göttingen Schilling Agents for controlling caries - contg. antibacterial enzymes, e.g. lysozyme or dextranase, in immobilised form to prevent dilution by saliva
EP0133736A2 (en) * 1983-06-06 1985-03-06 Laclede Professional Products, Inc. Di-enzymatic dentifrice

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2852792A1 (en) * 1977-12-06 1979-06-07 Anic Spa CARIES PREVENTIVE DENTALCLEANING COMPOSITION
DE2937964A1 (en) * 1979-09-20 1981-03-26 Peter 3400 Göttingen Schilling Agents for controlling caries - contg. antibacterial enzymes, e.g. lysozyme or dextranase, in immobilised form to prevent dilution by saliva
EP0133736A2 (en) * 1983-06-06 1985-03-06 Laclede Professional Products, Inc. Di-enzymatic dentifrice

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol 86 (1977), Abstract No 127293d, USSR 540637 *

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651433A1 (en) * 1989-09-07 1991-03-08 Dana Dominique Enzyme complex having activity with respect to tartar and dental caries
WO1991006217A1 (en) * 1989-10-27 1991-05-16 Genencor International Europe Oy A process of combatting microorganisms
US5607681A (en) * 1990-02-03 1997-03-04 The Boots Company Plc Anti-microbial compositions
EP0461530A3 (en) * 1990-06-13 1992-06-03 Haarmann & Reimer Corp. Synergistic antimicrobial compositions
WO1992010165A1 (en) * 1990-12-05 1992-06-25 Warner-Lambert Company Enzyme containing denture cleanser
US6294168B1 (en) 1991-02-21 2001-09-25 Exoxemis, Inc. Method for inhibiting pathogenic microbes in an animal using a haloperoxidase-halide-peroxide system
US5451402A (en) * 1991-02-21 1995-09-19 Exoxemis, Inc. Method for killing yeast and sporular microorganisms with haloperoxidase-containing compositions
US5510104A (en) * 1991-02-21 1996-04-23 Exoxemis, Inc. Method for killing or inhabiting the growth of sporulating microorganisms with haloperoxidase-containing compositions
US5565197A (en) * 1991-02-21 1996-10-15 Exoxemis, Inc. Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases
US5756090A (en) * 1991-02-21 1998-05-26 Eoe, Inc. Oxygen activatable formulations for disinfection or sterilization
US5718896A (en) * 1991-02-21 1998-02-17 Eoe, Inc. Methods for the inhibiting the transmission of sexually transmitted diseases
US6503507B1 (en) 1991-02-21 2003-01-07 Exoxemis, Inc. Oxygen activatable formulations for disinfection or sterilization
US6033662A (en) * 1991-02-21 2000-03-07 Exoxemis, Inc. Oxygen activatable formulations for disinfection or sterilization
EP0500387A3 (en) * 1991-02-21 1992-10-28 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora using haloperoxidase
US5389369A (en) * 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
US5888505A (en) * 1991-02-21 1999-03-30 Eoe, Inc. Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system
EP0923939A1 (en) * 1991-02-21 1999-06-23 Eoe, Inc. Methods and compositions for the treatment of infection and control of flora
US5250299A (en) * 1991-09-23 1993-10-05 Haarmann & Reimer Corp. Synergistic antimicrobial compositions
FR2685202A1 (en) * 1991-12-24 1993-06-25 Sederma Sa Novel method of pharmaceutical and cosmetic treatment for the regulation of seborrhoea, acne and the cutaneous flora
FR2695034A1 (en) * 1992-09-01 1994-03-04 Oreal Cosmetic or pharmaceutical composition comprising in combination a peroxidase and a singlet anti-oxygen agent.
EP0586303A1 (en) * 1992-09-01 1994-03-09 L'oreal Cosmetic or pharmaceutical composition containing an association between a peroxydase and an anti-singlet oxygen agent
US6316012B1 (en) 1992-09-01 2001-11-13 L'oreal Cosmetic or pharmaceutical composition comprising, in combination, a peroxidase and an anti-singlet oxygen agent
WO1995014784A1 (en) * 1993-11-24 1995-06-01 Monsanto Company Method of controlling plant pathogens
WO1996015682A1 (en) * 1994-11-22 1996-05-30 Ing. Erich Erber Kommanditgesellschaft Fodder and drinking water additive for improving the resistance to stress and immunity of useful animals
WO1997026908A1 (en) * 1996-01-23 1997-07-31 Semper Aktiebolag Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
US6149908A (en) * 1996-01-23 2000-11-21 Semper Ab Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating Helicobacter pylori infection
WO1998049272A3 (en) * 1997-04-29 1999-02-04 Knoll Ag Enzyme concentrate
US6312687B1 (en) 1997-04-29 2001-11-06 Knoll Aktiengesellschaft Stabilized lactoperoxidase and glucose oxidase concentrate
EP0994716B2 (en) † 1997-07-25 2007-07-04 Westgate Biological Limited Maternal immune secretions and their use in the treatment and/or prophylaxis of conditions of the human body
FR2777785A1 (en) * 1998-04-27 1999-10-29 Sederma Sa Cosmetic and dermopharmaceutical compositions containing horseradish peroxidase and caffeic acid
WO1999055301A1 (en) * 1998-04-27 1999-11-04 Sederma Use of horseradish peroxidase in cosmetic or dermopharmaceutical compositions for preventing and/or repairing skin damage induced by oxygen radical forms
EP1010430A4 (en) * 1998-04-30 2004-03-31 Snow Brand Milk Products Co Ltd Preventives and ameliorating agents for periodontosis
WO2001049241A3 (en) * 1999-12-29 2001-12-20 Dana Jean Dominique Bucco-dental hygiene
US6716611B2 (en) 1999-12-29 2004-04-06 Jean Dominique Dana Method for transforming cariogenic food sugars into acariogenic or cariostatic neutral products and composition therefor
FR2803199A1 (en) * 1999-12-29 2001-07-06 Jean Dominique Dana PROCESS FOR TRANSFORMATION OF CARIOGENOUS FOOD SUGARS INTO NEUTRAL ACARIOGENOUS OR CARIOSTATIC PRODUCTS AND COMPOSITION FOR IMPLEMENTATION
US8933147B2 (en) 2005-11-17 2015-01-13 3M Innovative Properties Company Anti-microbial dental impression material
WO2008041218A1 (en) * 2006-10-06 2008-04-10 Institute Of Technology Sligo Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme
US9522177B2 (en) 2006-10-06 2016-12-20 Institute Of Technology Sligo Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme
US9522165B2 (en) 2006-10-06 2016-12-20 Institute Of Technology Sligo Formulation and method for the treatment of fungal nail infections
EP2073836A4 (en) * 2006-10-10 2010-04-07 Laclede Inc Methods and compositions for the treatment of vaginal diseases employing peroxide-producing enzymes and peroxidases
AU2007307921B2 (en) * 2006-10-10 2013-03-28 Laclede, Inc. Methods and compositions for the treatment of vaginal diseases employing peroxide-producing enzymes and peroxidases
US9393249B2 (en) 2008-03-26 2016-07-19 Institute Of Technology Sligo Antimicrobial composition
US8945540B2 (en) 2008-05-09 2015-02-03 Exoxemis, Inc. Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
US10260061B2 (en) 2011-03-10 2019-04-16 Cornell University Mesoporous catalysts of magnetic nanoparticles and free-radical-producing enzymes, and methods of use
US10316313B2 (en) 2011-03-10 2019-06-11 Cornell University Mesoporous catalysts of magnetic nanoparticles and free-radical-producing enzymes, and methods of use
US9782459B2 (en) 2011-07-11 2017-10-10 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
KR101498510B1 (en) * 2012-06-26 2015-03-04 서울대학교산학협력단 Artificial salivary composition comprising hyalulonic acid
US12084649B2 (en) 2012-10-05 2024-09-10 Cornell University Hierarchical magnetic nanoparticle-enzyme mesoporous assemblies embedded in macroporous scaffolds
US11236322B2 (en) 2012-10-05 2022-02-01 Cornell University Enzyme forming mesoporous assemblies embedded in macroporous scaffolds
US10767172B2 (en) 2012-10-05 2020-09-08 Cornell University Method for epoxidation to produce alkene oxide
US10351841B2 (en) 2012-10-05 2019-07-16 Cornell University Method for inhibiting growth of microorganisms with macroporous scaffolds
EP3626310A1 (en) 2013-05-27 2020-03-25 Rakuto Bio Technologies Ltd. Enzymatic system containing cosmetic compositions
WO2014191995A2 (en) 2013-05-27 2014-12-04 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
US10980730B2 (en) 2013-05-27 2021-04-20 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
US11311017B2 (en) 2014-04-30 2022-04-26 Matoke Holdings Limited Antimicrobial compositions
US11185080B2 (en) 2014-04-30 2021-11-30 Matoke Holdings Limited Antimicrobial compositions
WO2015173022A1 (en) * 2014-05-12 2015-11-19 Jean-Dominique Dana Composition for improving oral and dental hygiene
FR3020758A1 (en) * 2014-05-12 2015-11-13 Jean-Dominique Dana COMPOSITION FOR IMPROVING BUCO-DENTAL HYGIENE
EP3603654A1 (en) * 2014-11-24 2020-02-05 Matoke Holdings Limited Prevention and treatment of microbial infections
US11517014B2 (en) 2015-05-18 2022-12-06 Zymtronix, Inc. Magnetically immobilized microbiocidal enzymes
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
EP3297442A4 (en) * 2015-05-18 2018-11-07 Zymtronix, LLC Magnetically immobilized microbiocidal enzymes
US10792649B2 (en) 2015-07-15 2020-10-06 Zymtronix, Llc Automated bionanocatalyst production
EP3192498A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192495A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192494A1 (en) * 2016-01-12 2017-07-19 Unilever PLC Oral care compositions
EP3192564B1 (en) * 2016-01-12 2024-07-10 Unilever IP Holdings B.V. Oral care composition comprising a protein for balancing the bacterial flora of the mouth
US10993436B2 (en) 2016-08-13 2021-05-04 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals
US12127557B2 (en) 2016-08-13 2024-10-29 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals
US12225905B2 (en) 2017-10-16 2025-02-18 Matoke Holdings Limited Antimicrobial superabsorbent compositions
US11730168B2 (en) 2017-10-16 2023-08-22 Matoke Holdings Limited Antimicrobial superabsorbent compositions
CN113317327A (en) * 2020-02-28 2021-08-31 中粮营养健康研究院有限公司 Bactericidal virucidal enzyme preparation composition and application thereof
CN115633706A (en) * 2022-09-27 2023-01-24 深圳市减化生物科技有限公司 Biological sterilization mildew removing agent, preparation method thereof and cleaning product

Also Published As

Publication number Publication date
DK501686A (en) 1988-04-21
FI882947L (en) 1988-06-20
EP0293407A1 (en) 1988-12-07
JPH01501000A (en) 1989-04-06
FI882947A0 (en) 1988-06-20
DK501686D0 (en) 1986-10-20
AU8175087A (en) 1988-05-06

Similar Documents

Publication Publication Date Title
WO1988002600A1 (en) Enzyme-containing bactericidal composition, and dental and wound treatment preparations comprising this composition
US4154815A (en) Zinc and enzyme toothpowder dentifrice
US4082841A (en) Dentifrice
US4150113A (en) Enzymatic dentifrices
US4537764A (en) Stabilized enzymatic dentifrice containing B-D-glucose and glucose oxidase
US4564519A (en) Di-enzymatic chewable dentifrice
US5908614A (en) Peroxidase-activating oral compositions
US4269822A (en) Antiseptic dentifrice
US4178362A (en) Enzymatic dentifrices
US4837009A (en) Method and composition for prevention of plaque formation and plaque dependent diseases
US5200171A (en) Oral health preparation and method
KR100613543B1 (en) Disinfectant for Cleaning
US4818519A (en) Method and composition for prevention of plaque formation and plaque dependent diseases
US5348734A (en) Oral health preparation and method
US5262151A (en) Stabilized enzymatic antimicrobial compositions
RU2289392C2 (en) Antibacterial agent for teeth cleaning, removing of dental plaque and respiratory refreshing
EP0907349B1 (en) Compositions for the removal of dental plaque
CA2496800C (en) Antiplaque enzyme containing dual component composition
AU769345B2 (en) Antimicrobial denture cleansing compositions
MXPA04011150A (en) Antibacterial dentifrice exhibiting enhanced antiplaque and breath freshening properties.
FI87423B (en) TANDVAORDSPRODUKT.
US3630924A (en) Preparation containing dextranase
EP1023037A1 (en) Plaque-inhibiting oral compositions
NO882708L (en) ENZYMOUS BACTERICIDE MIXTURE AND DENTAL AND SPARE TREATMENTS CONTAINING THE MIXTURE.
JPH0812544A (en) Oral cavity composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987907213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 882947

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1987907213

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987907213

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载